Abbott Laboratories agreed to pay state and federal authorities $1.6 billion to settle allegations it improperly marketed the drug Depakote for off-label uses.
Help on way for MS? Biogen Idec and Abbott Laboratories said Sunday a mid-stage study of their multiple sclerosis medicine daclizumab showed that the experimental drug worked better than placebo at preventing relapse of symptoms of the inflammatory disease.